252 related articles for article (PubMed ID: 9154872)
61. Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.
Fellrath JM; du Bois RM
Clin Exp Med; 2003 Sep; 3(2):65-83. PubMed ID: 14598183
[TBL] [Abstract][Full Text] [Related]
62. CT evaluation of fibrosing alveolitis--applications and insights.
Hansell DM; Wells AU
J Thorac Imaging; 1996; 11(4):231-49. PubMed ID: 8892193
[TBL] [Abstract][Full Text] [Related]
63. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.
Prior C; Haslam PL
Clin Exp Immunol; 1992 May; 88(2):280-7. PubMed ID: 1572093
[TBL] [Abstract][Full Text] [Related]
64. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years.
Rajasekaran A; Shovlin D; Saravanan V; Lord P; Kelly C
J Rheumatol; 2006 Jul; 33(7):1250-3. PubMed ID: 16758510
[TBL] [Abstract][Full Text] [Related]
65. Ventilation perfusion radionuclide imaging in cryptogenic fibrosing alveolitis.
Bourke SJ; Hawkins T; Keavey PM; Gascoigne AD; Corris PA
Nucl Med Commun; 1993 Jun; 14(6):454-64. PubMed ID: 8321484
[TBL] [Abstract][Full Text] [Related]
66. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.
Launay D; Remy-Jardin M; Michon-Pasturel U; Mastora I; Hachulla E; Lambert M; Delannoy V; Queyrel V; Duhamel A; Matran R; De Groote P; Hatron PY
J Rheumatol; 2006 Sep; 33(9):1789-801. PubMed ID: 16960939
[TBL] [Abstract][Full Text] [Related]
67. Gallium-67 scanning in the staging of cryptogenetic fibrosing alveolitis and hypersensitivity pneumonitis.
Vanderstappen M; Mornex JF; Lahneche B; Chauvot P; Bouvier JF; Wiesendanger T; Pages J; Webert P; Cordier JF; Brune J
Eur Respir J; 1988 Jun; 1(6):517-22. PubMed ID: 3169221
[TBL] [Abstract][Full Text] [Related]
68. An analysis of submaximal exercise responses in patients with sarcoidosis and fibrosing alveolitis.
Spiro SG; Dowdeswell IR; Clark TJ
Br J Dis Chest; 1981 Apr; 75(2):169-80. PubMed ID: 7272198
[TBL] [Abstract][Full Text] [Related]
69. Potential limitations of clinical criteria for the diagnosis of idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.
Peckham RM; Shorr AF; Helman DL
Respiration; 2004; 71(2):165-9. PubMed ID: 15031572
[TBL] [Abstract][Full Text] [Related]
70. Differences in Texture Analysis Parameters Between Active Alveolitis and Lung Fibrosis in Chest CT of Patients with Systemic Sclerosis: A Feasibility Study.
Kloth C; Blum AC; Thaiss WM; Preibsch H; Ditt H; Grimmer R; Fritz J; Nikolaou K; Bösmüller H; Horger M
Acad Radiol; 2017 Dec; 24(12):1596-1603. PubMed ID: 28807589
[TBL] [Abstract][Full Text] [Related]
71. Serial changes of cystic air spaces in fibrosing alveolitis: a CT-pathological study.
Mino M; Noma S; Kobashi Y; Iwata T
Clin Radiol; 1995 Jun; 50(6):357-63. PubMed ID: 7789018
[TBL] [Abstract][Full Text] [Related]
72. The assessment of respiratory function in a patient with dyspnoea and severe hypoxaemia.
Prediletto R; Formichi B; Allescia G; Paoletti P; Begliomini E; Fornai E; Pistolesi M; Giuntini C
Monaldi Arch Chest Dis; 1993; 48(3):213-20. PubMed ID: 8369786
[TBL] [Abstract][Full Text] [Related]
73. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.
Egan JJ; Stewart JP; Hasleton PS; Arrand JR; Carroll KB; Woodcock AA
Thorax; 1995 Dec; 50(12):1234-9. PubMed ID: 8553293
[TBL] [Abstract][Full Text] [Related]
74. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study.
Hubbard R; Johnston I; Britton J
Chest; 1998 Feb; 113(2):396-400. PubMed ID: 9498958
[TBL] [Abstract][Full Text] [Related]
75. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis.
Wallace WA; Roberts SN; Caldwell H; Thornton E; Greening AP; Lamb D; Howie SE
Thorax; 1994 Mar; 49(3):218-24. PubMed ID: 8202877
[TBL] [Abstract][Full Text] [Related]
76. Cryptogenic fibrosing alveolitis. A study of an indigenous African population.
Smith C; Feldman C; Levy H; Kallenbach JM; Zwi S
Respiration; 1990; 57(6):364-71. PubMed ID: 2099570
[TBL] [Abstract][Full Text] [Related]
77. Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis).
Haslam PL; Allan F; Watling AF; Barrett C; Morris L; Turner-Warwick M
Clin Exp Immunol; 1982 Jul; 49(1):59-66. PubMed ID: 7127903
[TBL] [Abstract][Full Text] [Related]
78. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.
Allanore Y; Devos-François G; Caramella C; Boumier P; Jounieaux V; Kahan A
Ann Rheum Dis; 2006 Jun; 65(6):834-5. PubMed ID: 16699057
[No Abstract] [Full Text] [Related]
79. Cardiovascular function at rest and on exercise in patients with cryptogenic fibrosing alveolitis.
Bush A; Busst CM
Thorax; 1988 Apr; 43(4):276-83. PubMed ID: 3406914
[TBL] [Abstract][Full Text] [Related]
80. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis.
De Santis M; Bosello S; La Torre G; Capuano A; Tolusso B; Pagliari G; Pistelli R; Danza FM; Zoli A; Ferraccioli G
Respir Res; 2005 Aug; 6(1):96. PubMed ID: 16107215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
